There are now several novel drugs targeting the protein kinase FLT3 in patients with acute myeloid leukemia (AML). Here, Keith Pratz, MD, of Johns Hopkins University, Baltimore, MD, discusses the clinical implications of these new agents and why they may provide an advantage over current treatments. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Recent advances in the targeting of FLT3 in AML
